Rib-X Pharmaceuticals Closes Tranche of $67.5M Financing.

Rib-X Pharmaceuticals Inc., a developer of treatments for acute bacterial skin and skin structure infections, has closed the first tranche of a $67.5 million Series 2 preferred stock financing. A second tranche is expected to close around the end of 2012, the company said in a press release. New investor Vatera Healthcare Partners led the latest infusion, which included existing shareholders Warburg Pincus, ABS Ventures and Vox Equity Partners.

North AmericaUSBriefs